Ubidecarenone

别名: Ubidecarenone Vitamin Q COQ10 ubiquinone coenzyme Q Coenzyme Q10 辅酶Q10; 癸烯醌;泛醌; 泛癸利酮; 辅酵素Q10; 2-(3,7,11,15,19,23,27,31,35,39-十甲基-2,6,10,14,18,22,26,30,34,38-四十碳十烯基)-5,6-二甲氧基-3-甲基-p-苯醌; 辅酶 Q-10;水溶性辅酶 Q-10;还原性辅酶 Q-10;还原及水溶性辅酶 Q-10;辅酶;Coenzyme Q10 辅酶Q10;泛癸利酮 EP标准品; 辅酶 Q10(Ubidecarenone);辅酶Q10 USP标准品;辅酶Q10 标准品;辅酶Q10 脂溶性抗氧化剂;辅酶Q10(Natural)(P)
目录号: V5575 纯度: ≥98%
辅酶 Q10 是电子传递链中的重要辅助因子,也是一种有效的抗氧化剂。
Ubidecarenone CAS号: 303-98-0
产品类别: New1
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
50mg
100mg
250mg
Other Sizes

Other Forms of Ubidecarenone:

  • Coenzyme Q10-d6
  • Coenzyme Q10-d9 (CoQ10-d9; Ubiquinone-10-d9)
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
辅酶 Q10 是电子传递链中的重要辅助因子,也是一种有效的抗氧化剂。
生物活性&实验参考方法
体外研究 (In Vitro)
辅酶 Q10 是每个细胞线粒体呼吸链的重要组成部分。因此,它在三磷酸腺苷 (ATP) 的合成中起着至关重要的作用,而三磷酸腺苷是大多数生物功能的能量来源。在高尔基体、线粒体、溶酶体和质膜内,辅酶 Q10 直接与自由基反应或将生育酚和抗坏血酸从氧化状态恢复,从而产生抗氧化作用 [1]。由于辅酶Q10被广泛认为是促进人类健康的重要成分,因此它是深受人们喜爱的膳食补充剂。由于其在线粒体功能和细胞生物能学中的重要作用,辅酶 Q10 已被提议作为一系列影响心血管系统、退行性神经系统和神经肌肉系统疾病的治疗剂 [2]。
体内研究 (In Vivo)
由于其疏水性和大分子量,膳食 CoQ10 吸收缓慢且程度有限。溶解的 CoQ10 配方在膳食补充剂方面表现出卓越的生物利用度。 Tmax 大约为 6 小时,消除半衰期大约为 33 小时。在健康个体中,血浆辅酶 Q10 参考区间为 0.40 至 1.91 mM。血浆CoQ10的增加与CoQ10补充剂的服用剂量之间存在相当显着的关系。对动物的研究表明,所有器官,包括心脏和大脑线粒体,都会吸收大量的 CoQ10 [2]。 CoQ10 治疗导致 12 个月大的大鼠大脑皮质线粒体中 CoQ10 浓度大幅上升。当口服辅酶Q10时,家族性肌萎缩侧索硬化症转基因小鼠模型的寿命更长,并且还显着减少了3-硝基丙酸全身治疗引起的纹状体损伤[3]。
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks. The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.
The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites. In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain. In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues. AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.
Metabolism / Metabolites
Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine. After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.
Biological Half-Life
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.
毒性/毒理 (Toxicokinetics/TK)
Hepatotoxicity
Coenzyme Q10 is generally recognized as safe and has not been linked to elevations in serum aminotransferase, alkaline phosphatase, or bilirubin levels. Despite wide scale use for several decades, there have been no convincing reports of clinically apparent liver injury due to coenzyme Q10.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
Drug Class: Nutritional Supplements
Other Names: Ubiquinone, Semiubiquinone, Ubiquinol, CoQ10
Protein Binding
In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL. The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.
参考文献

[1]. Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure, hypertension and endothelial dysfunction. Clin Chim Acta. 2015 Oct 23;450:83-9.

[2]. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53.

[3]. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.

其他信息
Coenzyme Q10 is a ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration. It has a role as a human metabolite, a ferroptosis inhibitor and an antioxidant.
Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand. Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.
Ubiquinone-10 is a metabolite found in or produced by Escherichia coli (strain K12, MG1655).
Coenzyme Q10, also known as ubiquinone, is an enzyme cofactor found in virtually all cells of the body and participates in many essential energy-producing and antioxidant enzymatic actions. While normally synthesized in the body in adequate amounts, coenzyme Q10 is used as a nutritional supplement for conditions highly dependent upon its actions, some of which are associated with low serum levels of the coenzyme. Coenzyme Q supplements are generally well tolerated and there is no evidence that they cause serum enzyme elevations or clinically apparent liver injury.
Coenzyme Q10 has been reported in Fusarium fujikuroi, Cytisus scoparius, and other organisms with data available.
Coenzyme Q10 is a naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)
See also: ... View More ...
Drug Indication
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies. It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
Mechanism of Action
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain. Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.
Pharmacodynamics
Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C59H90O4
分子量
863.36
精确质量
862.683
CAS号
303-98-0
相关CAS号
Coenzyme Q10-d6;110971-02-3;Coenzyme Q10-d9;2687960-97-8
PubChem CID
5281915
外观&性状
Yellow to orange solid powder
密度
1.0±0.1 g/cm3
沸点
869.0±65.0 °C at 760 mmHg
熔点
49-51 °C
闪点
324.6±34.3 °C
蒸汽压
0.0±3.3 mmHg at 25°C
折射率
1.526
LogP
20.93
tPSA
52.6
氢键供体(HBD)数目
0
氢键受体(HBA)数目
4
可旋转键数目(RBC)
31
重原子数目
63
分子复杂度/Complexity
1840
定义原子立体中心数目
0
SMILES
CC1=C(C(=O)C(=C(C1=O)OC)OC)C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C
InChi Key
ACTIUHUUMQJHFO-UPTCCGCDSA-N
InChi Code
InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
化学名
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
别名
Ubidecarenone Vitamin Q COQ10 ubiquinone coenzyme Q Coenzyme Q10
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意: (1). 请将本产品存放在密封且受保护的环境中(例如氮气保护),避免吸湿/受潮和光照。  (2). 该产品在溶液状态不稳定,请现配现用。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMF : 20 mg/mL (~23.17 mM)
Ethanol : ~2.5 mg/mL (~2.90 mM)
DMSO : ~1 mg/mL (~1.16 mM)
H2O : < 0.1 mg/mL
溶解度 (体内实验)
配方 1 中的溶解度: 3 mg/mL (3.47 mM) in 10% DMF 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 悬浮液;超声助溶。
*20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。

配方 2 中的溶解度: 13.33 mg/mL (15.44 mM) in 20% HP-β-CD in Saline (这些助溶剂从左到右依次添加,逐一添加), 悬浊液; 超声助溶。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.1583 mL 5.7913 mL 11.5827 mL
5 mM 0.2317 mL 1.1583 mL 2.3165 mL
10 mM 0.1158 mL 0.5791 mL 1.1583 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Role of Coenzyme Q10 in Chronic Kidney Disease
CTID: NCT05942027
Phase: Phase 4    Status: Recruiting
Date: 2024-11-29
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
CTID: NCT04444349
Phase: N/A    Status: Recruiting
Date: 2024-11-27
Ubiquinone Vs. Ubiquinol Supplementation
CTID: NCT06555575
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-21
A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)
CTID: NCT04752813
Phase: Phase 2    Status: Recruiting
Date: 2024-11-01
Effect Supplementation of COenzyme Q10 in Acute STEMI Underwent PPCI
CTID: NCT06661018
Phase: N/A    Status: Completed
Date: 2024-10-28
View More

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
CTID: NCT05422534
Phase: Phase 3    Status: Recruiting
Date: 2024-10-26


Effect of Coenzyme Q10 Administration on Polycystic Ovary Syndrome
CTID: NCT06659406
Phase: N/A    Status: Not yet recruiting
Date: 2024-10-26
Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
CTID: NCT06640465
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-10-16
--------
Randomized, double-blind study of nanoquinone versus placebo in patients with tinnitus aurium and low baseline blood levels of Q10
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2008-08-20
Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mortality).
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-07-23
TREATMENT OF IDIOPATHIC ASTHENOZOOSPERMIE WITH COENZYME Q10. A DOUBLE BLIND CONTROLLED STUDY
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-06-05
Improving Tolerability of Statins
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2006-05-30
Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-04-24
Clinical, morphological and biochemical effects of antioxidant treatment of patients with chronic hepatitis C.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2006-02-15
ubiquinone in Down syndrome
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-06-11

联系我们